<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="review-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">urmj</journal-id><journal-title-group><journal-title xml:lang="ru">Уральский медицинский журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Ural Medical Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2949-4389</issn><publisher><publisher-name>Ural State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.52420/2071-5943-2023-22-4-119-127</article-id><article-id custom-type="elpub" pub-id-type="custom">urmj-1299</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Литературные обзоры | Literature reviews</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Literature reviews</subject></subj-group></article-categories><title-group><article-title>Нарушение дофаминергической системы в патофизиологии сахарного диабета</article-title><trans-title-group xml:lang="en"><trans-title>Disruption of the dopaminergic system in the pathophysiology of diabetes mellitus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4705-3823</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Быков</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Bykov</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Юрий Витальевич Быков, кандидат медицинских наук, </p><p>Ставрополь</p></bio><bio xml:lang="en"><p>Yuri V. Bykov, Ph.D. in medicine, </p><p>Stavropol</p></bio><email xlink:type="simple">yubykov@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6892-3552</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Батурин</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Baturin</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Владимир Александрович Батурин, доктор медицинских наук, профессор, </p><p>Ставрополь</p></bio><bio xml:lang="en"><p>Vladimir A. Baturin, Doctor of Science (Medicine), Professor, </p><p>Stavropol</p></bio><email xlink:type="simple">baturin@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Ставропольский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Stavropol State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>13</day><month>08</month><year>2023</year></pub-date><volume>22</volume><issue>4</issue><fpage>119</fpage><lpage>127</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Быков Ю.В., Батурин В.А., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Быков Ю.В., Батурин В.А.</copyright-holder><copyright-holder xml:lang="en">Bykov Y.V., Baturin V.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.umjusmu.ru/jour/article/view/1299">https://www.umjusmu.ru/jour/article/view/1299</self-uri><abstract><sec><title>Введение</title><p>Введение. Сахарный диабет (СД) – наиболее распространенная эндокринопатия с высоким ростом заболеваемости и большим количеством осложнений.</p><p>Цель работы – провести аналитический обзор литературы с оценкой состояния проблемы нарушения дофаминергической системы при СД с патофизиологических позиций.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Поиск проведен в базах данных и электронных библиотеках Cochrane Library, PubMed, eLibrary, Medscape по поисковым словам: сахарный диабет (diabetes mellitus), дофамин (dopamine), инсулин (insulin), дофаминергическая система (dopaminergic system), диабетическая энцефалопатия (diabetic encephalopathy). Для обзора отобрано 66 источников.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Дисфункция дофаминергической системы может рассматриваться в качестве важного компонента патофизиологии СД. Гиперактивация выработки дофамина (ДА) на фоне СД ингибирует синтез инсулина, что приводит к гипергликемии. С другой стороны, гипоинсулинемия запускает активацию дофаминергической системы, формируя порочный круг. Увеличение выработки ДА при СД играет важную роль в формировании вторичной дисфункции центральной нервной системы, в первую очередь за счет развития церебральной недостаточности. Многочисленные доклинические исследования подтверждают дисфункцию дофаминергической системы (ее активацию) при СД. Клинические исследования по данной проблематике малочисленны и требуют дальнейшего изучения.</p></sec><sec><title>Заключение</title><p>Заключение. Дисфункция дофаминергической системы при СД является актуальным направлением изучения патофизиологии симптомов неврологических нарушений данного заболевания. СД 1 и 2 типа − патогенетически разные заболевания, и поэтому нарушения выработки ДА могут быть обусловлены недостаточностью инсулина у больных с СД 1 типа, разными сроками манифестации, с гиперинсулинемией и инсулинорезистентностью при СД 2 типов. Поиск достоверных методов диагностики дисфункции дофаминергической системы может улучшить понимание происходящих патологических процессов в нейроэндокринной системе при СД, что важно в решении вопросов их коррекции в дополнение к патогенетической терапии.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Diabetes mellitus (DM) is the most common endocrinopathy with a high incidence and a high number of complications.</p><p>The aim of this work was to conduct an analytical literature review assessing the state of the problem of dopaminergic dysfunction in diabetes from a pathophysiological perspective.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Searching Cochrane Library, PubMed, eLibrary, Medscape databases and digital libraries using the search words: diabetes mellitus, dopamine, insulin, dopaminergic system, diabetic encephalopathy. A total of 66 sources were selected for the review.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. Dopaminergic system dysfunction can be considered an important component of the pathophysiology of diabetes. Hyperactivation of dopamine (DA) production in the setting of diabetes inhibits insulin synthesis, resulting in hyperglycemia. On the other hand, hypoinsulinemia triggers activation of the dopaminergic system, forming a vicious circle. Increased DA production in diabetes plays an important role in the development of secondary central nervous system dysfunction, primarily through the development of cerebral insufficiency. Numerous preclinical studies confirm the dysfunction of the dopaminergic system (its activation) in diabetes. Clinical studies on this issue are scarce and require further investigation.</p></sec><sec><title>Conclusion</title><p>Conclusion. Dysfunction of the dopaminergic system in diabetes is an important area of research into the pathophysiology of symptomatic neurological disorders in this disease. Type 1 and type 2 diabetes are pathogenetically different diseases, and therefore impaired DA production may be due to insulin deficiency in patients with type 1 diabetes, different timing of manifestation, with hyperinsulinemia and insulin resistance in type 2 diabetes. Finding reliable methods to diagnose dysfunction of the dopaminergic system may improve understanding of the ongoing pathological processes in the neuroendocrine system in diabetes, which is important in addressing their correction in addition to pathogenetic therapy.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>сахарный диабет</kwd><kwd>дофаминергическая система</kwd><kwd>дофамин</kwd><kwd>инсулин</kwd><kwd>церебральная недостаточность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>diabetes mellitus</kwd><kwd>dopaminergic system</kwd><kwd>dopamine</kwd><kwd>insulin</kwd><kwd>cerebral insufficiency</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Piątkowska-Chmiel I, Gawrońska-Grzywacz M, Popiołek Ł et al. The novel adamantane derivatives as potential mediators of inflammation and neural plasticity in diabetes mice with cognitive impairment. Sci Rep. 2022;12(1):6708. https://doi.org/10.1038/s41598-022-10187-y.</mixed-citation><mixed-citation xml:lang="en">Piątkowska-Chmiel I, Gawrońska-Grzywacz M, Popiołek Ł et al. The novel adamantane derivatives as potential mediators of inflammation and neural plasticity in diabetes mice with cognitive impairment. Sci Rep. 2022;12(1):6708. https://doi.org/10.1038/s41598-022-10187-y.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Pignalosa FC, Desiderio A, Mirra P et al. Diabetes and cognitive impairment: a role for glucotoxicity and dopaminergic dysfunction. Int J Mol Sci. 2021;22(22):12366. https://doi.org/10.3390/ijms222212366.</mixed-citation><mixed-citation xml:lang="en">Pignalosa FC, Desiderio A, Mirra P et al. Diabetes and cognitive impairment: a role for glucotoxicity and dopaminergic dysfunction. Int J Mol Sci. 2021;22(22):12366. https://doi.org/10.3390/ijms222212366.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Hassan A, Sharma Kandel R, Mishra R et al. Diabetes mellitus and parkinson’s disease: shared pathophysiological links and possible therapeutic implications. Cureus. 2020;12(8):e9853. https://doi.org/10.7759/cureus.9853.</mixed-citation><mixed-citation xml:lang="en">Hassan A, Sharma Kandel R, Mishra R et al. Diabetes mellitus and parkinson’s disease: shared pathophysiological links and possible therapeutic implications. Cureus. 2020;12(8):e9853. https://doi.org/10.7759/cureus.9853.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Raghavan S, Vassy JL, Ho YL et al. Diabetes Mellitus-related all-cause and cardiovascular mortality in a national cohort of adults. J Am Heart Assoc. 2019;8:011295. https://doi.org/10.1161/JAHA.118.011295.</mixed-citation><mixed-citation xml:lang="en">Raghavan S, Vassy JL, Ho YL et al. Diabetes Mellitus-related all-cause and cardiovascular mortality in a national cohort of adults. J Am Heart Assoc. 2019;8:011295. https://doi.org/10.1161/JAHA.118.011295.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Petersmann A, Müller-Wieland D, Müller UA et al. Definition, classification and diagnosis of diabetes mellitus. Exp Clin Endocrinol Diabetes 2019;127:S1–S7. https://doi.org/10.1055/a-1018-9078.</mixed-citation><mixed-citation xml:lang="en">Petersmann A, Müller-Wieland D, Müller UA et al. Definition, classification and diagnosis of diabetes mellitus. Exp Clin Endocrinol Diabetes 2019;127:S1–S7. https://doi.org/10.1055/a-1018-9078.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Harding JL, Pavkov ME, Magliano DJ et al. Global trends in diabetes complications: A review of current evidence. Diabetologia. 2019;62:3–16. https://doi.org/10.1007/s00125-018-4711-2.</mixed-citation><mixed-citation xml:lang="en">Harding JL, Pavkov ME, Magliano DJ et al. Global trends in diabetes complications: A review of current evidence. Diabetologia. 2019;62:3–16. https://doi.org/10.1007/s00125-018-4711-2.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Small DM. Dopamine adaptations as a common pathway for neurocognitive impairment in diabetes and obesity: a neuropsychological perspective. Front Neurosci. 2017;11:134. https://doi.org/10.3389/fnins.2017.00134.</mixed-citation><mixed-citation xml:lang="en">Small DM. Dopamine adaptations as a common pathway for neurocognitive impairment in diabetes and obesity: a neuropsychological perspective. Front Neurosci. 2017;11:134. https://doi.org/10.3389/fnins.2017.00134.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ke C, Narayan KMV, Chan JCN et al. Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations. Nat Rev Endocrinol. 2022;18(7):413-432. https://doi.org/10.1038/s41574-022-00669-4.</mixed-citation><mixed-citation xml:lang="en">Ke C, Narayan KMV, Chan JCN et al. Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations. Nat Rev Endocrinol. 2022;18(7):413-432. https://doi.org/10.1038/s41574-022-00669-4.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Fiory F, Perruolo G, Cimmino I et al. The relevance of insulin action in the dopaminergic system. Front Neurosci. 2019;13:868. https://doi.org/10.3389/fnins.2019.00868.</mixed-citation><mixed-citation xml:lang="en">Fiory F, Perruolo G, Cimmino I et al. The relevance of insulin action in the dopaminergic system. Front Neurosci. 2019;13:868. https://doi.org/10.3389/fnins.2019.00868.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng H, Gang X, Liu Y et al. Mitochondrial dysfunction plays a key role in the development of neurodegenerative diseases in diabetes. Am J Physiol Endocrinol Metab. 2020;318:E750–E764. https://doi.org/10.1152/ajpendo.00179.2019.</mixed-citation><mixed-citation xml:lang="en">Cheng H, Gang X, Liu Y et al. Mitochondrial dysfunction plays a key role in the development of neurodegenerative diseases in diabetes. Am J Physiol Endocrinol Metab. 2020;318:E750–E764. https://doi.org/10.1152/ajpendo.00179.2019.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Mimenza-Alvarado AJ, Jiménez-Castillo GA, Yeverino-Castro SG et al. Effect of poor glycemic control in cognitive performance in the elderly with type 2 diabetes mellitus: the Mexican health and aging study. BMC Geriatr. 2020;20:424. https://doi.org/10.1186/s12877-020-01827-x.</mixed-citation><mixed-citation xml:lang="en">Mimenza-Alvarado AJ, Jiménez-Castillo GA, Yeverino-Castro SG et al. Effect of poor glycemic control in cognitive performance in the elderly with type 2 diabetes mellitus: the Mexican health and aging study. BMC Geriatr. 2020;20:424. https://doi.org/10.1186/s12877-020-01827-x.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">de Donato A, Buonincontri V, Borriello G et al. The dopamine system: insights between kidney and brain. Kidney Blood Press Res. 2022;47(8):493-505. https://doi.org/10.1159/000522132.</mixed-citation><mixed-citation xml:lang="en">de Donato A, Buonincontri V, Borriello G et al. The dopamine system: insights between kidney and brain. Kidney Blood Press Res. 2022;47(8):493-505. https://doi.org/10.1159/000522132.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Luo SX, Huang EJ. Dopaminergic Neurons and Brain Reward Pathways: From Neurogenesis to Circuit Assembly. Am J Pathol. 2016;186:478–488. https://doi.org/10.1016/j.ajpath.2015.09.023.</mixed-citation><mixed-citation xml:lang="en">Luo SX, Huang EJ. Dopaminergic Neurons and Brain Reward Pathways: From Neurogenesis to Circuit Assembly. Am J Pathol. 2016;186:478–488. https://doi.org/10.1016/j.ajpath.2015.09.023.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Morel C, Montgomery SE, Li L. Midbrain projection to the basolateral amygdala encodes anxiety-like but not depressionlike behaviors. Nat Commun. 2022;131:1–13. https://doi.org/10.1038/s41467-022-29155-1.</mixed-citation><mixed-citation xml:lang="en">Morel C, Montgomery SE, Li L. Midbrain projection to the basolateral amygdala encodes anxiety-like but not depressionlike behaviors. Nat Commun. 2022;131:1–13. https://doi.org/10.1038/s41467-022-29155-1.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Amin M, Wu R, Postolache TT, Gragnoli C. Linkage and association of novel DRD2 variants to the comorbidity of type 2 diabetes and depression. Eur Rev Med Pharmacol Sci. 2022;26(22):8370−8375. https://doi.org/10.26355/eurrev_202211_30372.</mixed-citation><mixed-citation xml:lang="en">Amin M, Wu R, Postolache TT, Gragnoli C. Linkage and association of novel DRD2 variants to the comorbidity of type 2 diabetes and depression. Eur Rev Med Pharmacol Sci. 2022;26(22):8370−8375. https://doi.org/10.26355/eurrev_202211_30372.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Shpakov AO, Derkach KV, Berstein LM. Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases. Future Sci. OA 2015;1(3):SO25. https://doi.org/10.4155/fso.15.23.</mixed-citation><mixed-citation xml:lang="en">Shpakov AO, Derkach KV, Berstein LM. Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases. Future Sci. OA 2015;1(3):SO25. https://doi.org/10.4155/fso.15.23.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Carli M, Kolachalam S, Aringhieri S et al. Dopamine D2 receptors dimers: how can we pharmacologically target them? Curr Neuropharmacol. 2018;16(2):222−230. https://doi.org/10.2174/1570159X15666170518151127.</mixed-citation><mixed-citation xml:lang="en">Carli M, Kolachalam S, Aringhieri S et al. Dopamine D2 receptors dimers: how can we pharmacologically target them? Curr Neuropharmacol. 2018;16(2):222−230. https://doi.org/10.2174/1570159X15666170518151127.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Xi Y, Wen X, Zhang Y et al. DR1 activation inhibits the proliferation of vascular smooth muscle cells through increasing endogenous H2S in diabetes. Aging Dis. 2022;13(3):910-926. https://doi.org/10.14336/AD.2021.1104.</mixed-citation><mixed-citation xml:lang="en">Xi Y, Wen X, Zhang Y et al. DR1 activation inhibits the proliferation of vascular smooth muscle cells through increasing endogenous H2S in diabetes. Aging Dis. 2022;13(3):910-926. https://doi.org/10.14336/AD.2021.1104.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Klein MO, Battagello DS, Cardoso AR et al. Dopamine: functions, signaling, and association with neurological diseases. Cell Mol Neurobiol. 2019;39:31–59. https://doi.org/10.1007/s10571-018-0632-3.</mixed-citation><mixed-citation xml:lang="en">Klein MO, Battagello DS, Cardoso AR et al. Dopamine: functions, signaling, and association with neurological diseases. Cell Mol Neurobiol. 2019;39:31–59. https://doi.org/10.1007/s10571-018-0632-3.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Wang S, Che T, Levit A et al. Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Nature. 2018;555:269−273. https://doi.org/10.1038/nature25758.</mixed-citation><mixed-citation xml:lang="en">Wang S, Che T, Levit A et al. Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Nature. 2018;555:269−273. https://doi.org/10.1038/nature25758.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Gasecka A, Siwik D, Gajewska M et al. Early biomarkers of neurodegenerative and neurovascular disorders in diabetes. J Clin Med. 2020;9(9):2807. https://doi.org/10.3390/jcm9092807.</mixed-citation><mixed-citation xml:lang="en">Gasecka A, Siwik D, Gajewska M et al. Early biomarkers of neurodegenerative and neurovascular disorders in diabetes. J Clin Med. 2020;9(9):2807. https://doi.org/10.3390/jcm9092807.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Hamamah S, Aghazarian A, Nazaryan A et al. Role of microbiota-gut-brain axis in regulating dopaminergic signaling. Biomedicines. 2022;10(2):436. https://doi.org/10.3390/biomedicines10020436.</mixed-citation><mixed-citation xml:lang="en">Hamamah S, Aghazarian A, Nazaryan A et al. Role of microbiota-gut-brain axis in regulating dopaminergic signaling. Biomedicines. 2022;10(2):436. https://doi.org/10.3390/biomedicines10020436.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Munuera J, Burguière E. Can we tackle climate change by behavioral hacking of the dopaminergic system? Front Behav Neurosci. 2022;16:996955. https://doi.org/10.3389/fnbeh.2022.996955.</mixed-citation><mixed-citation xml:lang="en">Munuera J, Burguière E. Can we tackle climate change by behavioral hacking of the dopaminergic system? Front Behav Neurosci. 2022;16:996955. https://doi.org/10.3389/fnbeh.2022.996955.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Bucolo C, Leggio GM, Drago F, Salomone S. Dopamine outside the brain: the eye, cardiovascular system and endocrine pancreas. Pharmacol Ther. 2019;203:107392. https://doi.org/10.1016/j.pharmthera.2019.07.003.</mixed-citation><mixed-citation xml:lang="en">Bucolo C, Leggio GM, Drago F, Salomone S. Dopamine outside the brain: the eye, cardiovascular system and endocrine pancreas. Pharmacol Ther. 2019;203:107392. https://doi.org/10.1016/j.pharmthera.2019.07.003.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Farino ZJ, Morgenstern TJ, Maffei A et al. New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretion. Mol Psychiatry. 2020;25(9):2070−2085. https://doi.org/10.1038/s41380-018-0344-6.</mixed-citation><mixed-citation xml:lang="en">Farino ZJ, Morgenstern TJ, Maffei A et al. New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretion. Mol Psychiatry. 2020;25(9):2070−2085. https://doi.org/10.1038/s41380-018-0344-6.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Korner J, Cline GW, Slifstein M et al. A role for foregut tyrosine metabolism in glucose tolerance. Mol Metab. 2019;23:37– 50. https://doi.org/10.1016/j.molmet.2019.02.008.</mixed-citation><mixed-citation xml:lang="en">Korner J, Cline GW, Slifstein M et al. A role for foregut tyrosine metabolism in glucose tolerance. Mol Metab. 2019;23:37– 50. https://doi.org/10.1016/j.molmet.2019.02.008.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Q, Tang Q, Purohit NM et al. Food-induced dopamine signaling in AgRP neurons promotes feeding. Cell Rep. 2022;41(9):111718. https://doi.org/10.1016/j.celrep.2022.111718.</mixed-citation><mixed-citation xml:lang="en">Zhang Q, Tang Q, Purohit NM et al. Food-induced dopamine signaling in AgRP neurons promotes feeding. Cell Rep. 2022;41(9):111718. https://doi.org/10.1016/j.celrep.2022.111718.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Leite F, Ribeiro L. Dopaminergic pathways in obesity-associated inflammation. J Neuroimmune Pharmacol. 2020;15(1):93−113. https://doi.org/10.1007/s11481-019-09863-0.</mixed-citation><mixed-citation xml:lang="en">Leite F, Ribeiro L. Dopaminergic pathways in obesity-associated inflammation. J Neuroimmune Pharmacol. 2020;15(1):93−113. https://doi.org/10.1007/s11481-019-09863-0.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Riedel S, Pheiffer C, Johnson R et al. Intestinal barrier function and immune homeostasis are missing links in obesity and type 2 diabetes development. Front Endocrinol (Lausanne). 2022;12:833544. https://doi.org/10.3389/fendo.2021.833544.</mixed-citation><mixed-citation xml:lang="en">Riedel S, Pheiffer C, Johnson R et al. Intestinal barrier function and immune homeostasis are missing links in obesity and type 2 diabetes development. Front Endocrinol (Lausanne). 2022;12:833544. https://doi.org/10.3389/fendo.2021.833544.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Kawano M, Takagi R, Saika K et al. Dopamine regulates cytokine secretion during innate and adaptive immune responses. Int Immunol. 2018;30:591–606. https://doi.org/10.1093/intimm/dxy057.</mixed-citation><mixed-citation xml:lang="en">Kawano M, Takagi R, Saika K et al. Dopamine regulates cytokine secretion during innate and adaptive immune responses. Int Immunol. 2018;30:591–606. https://doi.org/10.1093/intimm/dxy057.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Olivares-Hernández A, Figuero-Pérez L, Cruz-Hernandez JJ et al. Dopamine receptors and the kidney: an overview of health- and pharmacological-targeted implications. Biomolecules. 2021;11(2):254. https://doi.org/10.3390/biom11020254.</mixed-citation><mixed-citation xml:lang="en">Olivares-Hernández A, Figuero-Pérez L, Cruz-Hernandez JJ et al. Dopamine receptors and the kidney: an overview of health- and pharmacological-targeted implications. Biomolecules. 2021;11(2):254. https://doi.org/10.3390/biom11020254.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Быков Ю.В. Роль оксидативного стресса в развитии осложнений при сахарном диабете. Медицинский вестник Северного Кавказа. 2022;3:322−327. https://doi.org/10.14300/mnnc.2022.17080.</mixed-citation><mixed-citation xml:lang="en">Bykov YuV. Role of oxidative stress in the development of complications with diabetes mellitus. Medical News of North Caucasus. 2022;3:322−327. (In Russ.). https://doi.org/10.14300/mnnc.2022.17080.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Быков Ю.В., Батурин В.А. Роль оксидативного стресса в патофизиологии сахарного диабета 1-го типа. Патогенез. 2022);20(4):35−39. https://doi.org/https://doi.org/10.25557/2310-0435.2022.04.35-39</mixed-citation><mixed-citation xml:lang="en">Bykov YuV, Baturin VA. The role of oxidative stress in the pathophysiology of type 1 diabetes mellitus. Patogenez = Pathogenesis. 2022;20(4):35−39. https://doi.org/10.25557/2310-0435.2022.04.35-39.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Быков Ю.В., Батурин В.А., Волков Е.В. Уровень аутоантител к дофаминовым и NMDA рецепторам у детей в зависимости от степени тяжести диабетического кетоацидоза. Забайкальский медицинский вестник. 2022;3:18-26. https://doi.org/10.52485/19986173_2022_3_18.</mixed-citation><mixed-citation xml:lang="en">Bykov YuV, Baturin VA, Volkov EV. The level of autoantibodies to dopamine and NMDA receptors in children depending on the severity of diabetic ketoacidosis. Zabajkal’skij meditsinskij vestnik = Zabaikalsky Medical Bulletin. 2022;3:18-26. https://doi.org/10.52485/19986173_2022_3_18.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Hong CT, Chen KY, Wang W et al. Insulin resistance promotes parkinson’s disease through aberrant expression of α-synuclein, mitochondrial dysfunction, and deregulation of the polo-like kinase 2 signaling. Cells. 2020;9:740. https://doi.org/10.3390/cells9030740.</mixed-citation><mixed-citation xml:lang="en">Hong CT, Chen KY, Wang W et al. Insulin resistance promotes parkinson’s disease through aberrant expression of α-synuclein, mitochondrial dysfunction, and deregulation of the polo-like kinase 2 signaling. Cells. 2020;9:740. https://doi.org/10.3390/cells9030740.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Eftekharpour E, Fernyhough P. Oxidative stress and mitochondrial dysfunction associated with peripheral neuropathy in type 1 diabetes. Antioxid Redox Signal. 2022;37(7−9):578−596. https://doi.org/10.1089/ars.2021.0152.</mixed-citation><mixed-citation xml:lang="en">Eftekharpour E, Fernyhough P. Oxidative stress and mitochondrial dysfunction associated with peripheral neuropathy in type 1 diabetes. Antioxid Redox Signal. 2022;37(7−9):578−596. https://doi.org/10.1089/ars.2021.0152.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Conio B, Martino M, Magioncalda P et al. Opposite effects of dopamine and serotonin on resting-state networks: review and implications for psychiatric disorders. Mol Psychiatry. 2020;25:82−93. https://doi.org/10.1038/s41380-019-0406-4.</mixed-citation><mixed-citation xml:lang="en">Conio B, Martino M, Magioncalda P et al. Opposite effects of dopamine and serotonin on resting-state networks: review and implications for psychiatric disorders. Mol Psychiatry. 2020;25:82−93. https://doi.org/10.1038/s41380-019-0406-4.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Bharadwaj P, Wijesekara N, Liyanapathirana M et al. The link between type 2 diabetes and neurodegeneration: roles for amyloid-β, amylin, and tau proteins. J Alzheimer’s Dis. 2017;59:421–432. https://doi.org/10.3233/JAD-161192.</mixed-citation><mixed-citation xml:lang="en">Bharadwaj P, Wijesekara N, Liyanapathirana M et al. The link between type 2 diabetes and neurodegeneration: roles for amyloid-β, amylin, and tau proteins. J Alzheimer’s Dis. 2017;59:421–432. https://doi.org/10.3233/JAD-161192.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Andersen IB, Andreassen M, Krogh J. The effect of dopamine agonists on metabolic variables in adults with type 2 diabetes: A systematic review with meta analysis and trial sequential analysis of randomized clinical trials. Diabetes Obes Metab. 2021;23:58−67. https://doi.org/10.1111/dom.14183.</mixed-citation><mixed-citation xml:lang="en">Andersen IB, Andreassen M, Krogh J. The effect of dopamine agonists on metabolic variables in adults with type 2 diabetes: A systematic review with meta analysis and trial sequential analysis of randomized clinical trials. Diabetes Obes Metab. 2021;23:58−67. https://doi.org/10.1111/dom.14183.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Rivera-Mancilla E, Altamirano-Espinoza AH, Manrique-Maldonado G et al. Streptozotocin-induced diabetes in rats modifies the role D2, D3 and D4 dopamine receptors play in cardiac sympathetic inhibition. Basic Clin Pharmacol Toxicol. 2022;131(4):262−269. https://doi.org/10.1111/bcpt.13774.</mixed-citation><mixed-citation xml:lang="en">Rivera-Mancilla E, Altamirano-Espinoza AH, Manrique-Maldonado G et al. Streptozotocin-induced diabetes in rats modifies the role D2, D3 and D4 dopamine receptors play in cardiac sympathetic inhibition. Basic Clin Pharmacol Toxicol. 2022;131(4):262−269. https://doi.org/10.1111/bcpt.13774.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Pérez-Taboada I, Alberquilla S, Martín ED et al. Diabetes Causes Dysfunctional Dopamine Neurotransmission Favoring Nigrostriatal Degeneration in Mice. Mov Disord. 2020;35:1636–1648. https://doi.org/10.1002/mds.28124.</mixed-citation><mixed-citation xml:lang="en">Pérez-Taboada I, Alberquilla S, Martín ED et al. Diabetes Causes Dysfunctional Dopamine Neurotransmission Favoring Nigrostriatal Degeneration in Mice. Mov Disord. 2020;35:1636–1648. https://doi.org/10.1002/mds.28124.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Lee SE, Han K, Baek JY et al. Taskforce Team for Diabetes Fact Sheet of the Korean Diabetes Association Association Between Diabetic Retinopathy and Parkinson Disease: The Korean National Health Insurance Service Database. J Clin Endocrinol Metab. 2018;103:3231–3238. https://doi.org/10.1210/jc.2017-02774.</mixed-citation><mixed-citation xml:lang="en">Lee SE, Han K, Baek JY et al. Taskforce Team for Diabetes Fact Sheet of the Korean Diabetes Association Association Between Diabetic Retinopathy and Parkinson Disease: The Korean National Health Insurance Service Database. J Clin Endocrinol Metab. 2018;103:3231–3238. https://doi.org/10.1210/jc.2017-02774.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Vicchi FL, Luque GM, Brie B et al. Dopaminergic drugs in type 2 diabetes and glucose homeostasis. Pharmacol Res. 2016;109:74–80. https://doi.org/10.1016/j.phrs.2015.12.029.</mixed-citation><mixed-citation xml:lang="en">Vicchi FL, Luque GM, Brie B et al. Dopaminergic drugs in type 2 diabetes and glucose homeostasis. Pharmacol Res. 2016;109:74–80. https://doi.org/10.1016/j.phrs.2015.12.029.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Pagano G, Polychronis S, Wilson H et al. Diabetes mellitus and Parkinson disease. Neurology. 2018;90:e1654–e1662. https://doi.org/10.1212/WNL.0000000000005475.</mixed-citation><mixed-citation xml:lang="en">Pagano G, Polychronis S, Wilson H et al. Diabetes mellitus and Parkinson disease. Neurology. 2018;90:e1654–e1662. https://doi.org/10.1212/WNL.0000000000005475.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Shokrzadeh M, Mirshafa A, Yekta Moghaddam N et al. Mitochondrial dysfunction contribute to diabetic neurotoxicity induced by streptozocin in mice: protective effect of Urtica dioica and pioglitazone. Toxicol Mech Methods. 2018;28:499–506. https://doi.org/10.1080/15376516.2018.1459993.</mixed-citation><mixed-citation xml:lang="en">Shokrzadeh M, Mirshafa A, Yekta Moghaddam N et al. Mitochondrial dysfunction contribute to diabetic neurotoxicity induced by streptozocin in mice: protective effect of Urtica dioica and pioglitazone. Toxicol Mech Methods. 2018;28:499–506. https://doi.org/10.1080/15376516.2018.1459993.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Rom S, Zuluaga-Ramirez V, Gajghate S, Seliga A et al. Hyperglycemia-Driven neuroinflammation compromises BBB leading to memory loss in both diabetes mellitus (DM) Type 1 and Type 2 mouse models. Mol Neurobiol. 2018;56:1883– 1896. https://doi.org/10.1007/s12035-018-1195-5.</mixed-citation><mixed-citation xml:lang="en">Rom S, Zuluaga-Ramirez V, Gajghate S, Seliga A et al. Hyperglycemia-Driven neuroinflammation compromises BBB leading to memory loss in both diabetes mellitus (DM) Type 1 and Type 2 mouse models. Mol Neurobiol. 2018;56:1883– 1896. https://doi.org/10.1007/s12035-018-1195-5.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Simo R, Ciudin A, Simo-Servat O, Hernandez C. Cognitive impairment and dementia: a new emerging complication of type 2 diabetes-The diabetologist’s perspective. Acta Diabetol. 2017;54:417–424. https://doi.org/10.1007/s00592-017-0970-975.</mixed-citation><mixed-citation xml:lang="en">Simo R, Ciudin A, Simo-Servat O, Hernandez C. Cognitive impairment and dementia: a new emerging complication of type 2 diabetes-The diabetologist’s perspective. Acta Diabetol. 2017;54:417–424. https://doi.org/10.1007/s00592-017-0970-975.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Koekkoek PS, Kappelle LJ, van den Berg E et al. Cognitive function in patients with diabetes mellitus: Guidance for daily care. Lancet Neurol. 2015;14:329–340. https://doi.org/10.1016/S1474-4422(14)70249-2.</mixed-citation><mixed-citation xml:lang="en">Koekkoek PS, Kappelle LJ, van den Berg E et al. Cognitive function in patients with diabetes mellitus: Guidance for daily care. Lancet Neurol. 2015;14:329–340. https://doi.org/10.1016/S1474-4422(14)70249-2.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Grieco M, Giorgi A, Gentile MC et al. Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases. Front Neurosci. 2019;13:1112. https://doi.org/10.3389/fnins.2019.01112.</mixed-citation><mixed-citation xml:lang="en">Grieco M, Giorgi A, Gentile MC et al. Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases. Front Neurosci. 2019;13:1112. https://doi.org/10.3389/fnins.2019.01112.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Sergi D, Renaud J, Simola N, Martinoli MG. Diabetes, a Contemporary Risk for Parkinson’s Disease: Epidemiological and Cellular Evidences. Front Aging Neurosci. 2019;11:302. https://doi.org/10.3389/fnagi.2019.00302.</mixed-citation><mixed-citation xml:lang="en">Sergi D, Renaud J, Simola N, Martinoli MG. Diabetes, a Contemporary Risk for Parkinson’s Disease: Epidemiological and Cellular Evidences. Front Aging Neurosci. 2019;11:302. https://doi.org/10.3389/fnagi.2019.00302.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">De Iuliis A, Montinaro E, Fatati G et al. Diabetes mellitus and Parkinson’s disease: dangerous liaisons between insulin and dopamine. Neural Regen Res. 2022;17(3):523−533. https://doi.org/10.4103/1673-5374.320965.</mixed-citation><mixed-citation xml:lang="en">De Iuliis A, Montinaro E, Fatati G et al. Diabetes mellitus and Parkinson’s disease: dangerous liaisons between insulin and dopamine. Neural Regen Res. 2022;17(3):523−533. https://doi.org/10.4103/1673-5374.320965.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Bini J, Sanchez-Rangel E, Gallezot JD et al. PET imaging of pancreatic dopamine D2 and D3 receptor density with 11C-(+)-PHNO in type 1 diabetes. J Nucl Med. 2020;61:570–576. https://doi.org/10.2967/jnumed.119.234013.</mixed-citation><mixed-citation xml:lang="en">Bini J, Sanchez-Rangel E, Gallezot JD et al. PET imaging of pancreatic dopamine D2 and D3 receptor density with 11C-(+)-PHNO in type 1 diabetes. J Nucl Med. 2020;61:570–576. https://doi.org/10.2967/jnumed.119.234013.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Labandeira CM, Fraga-Bau A, Arias Ron D et al. Parkinson’s disease and diabetes mellitus: common mechanisms and treatment repurposing. Neural Regen Res. 2022;17(8):1652−1658. https://doi.org/10.4103/1673-5374.332122.</mixed-citation><mixed-citation xml:lang="en">Labandeira CM, Fraga-Bau A, Arias Ron D et al. Parkinson’s disease and diabetes mellitus: common mechanisms and treatment repurposing. Neural Regen Res. 2022;17(8):1652−1658. https://doi.org/10.4103/1673-5374.332122.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Chaudhry S, Bernardes M, Harris PE, Maffei A. Gastrointestinal dopamine as an anti-incretin and its possible role in bypass surgery as therapy for type 2 diabetes with associated obesity. Minerva Endocrinol. 2016;41(1):43–56.</mixed-citation><mixed-citation xml:lang="en">Chaudhry S, Bernardes M, Harris PE, Maffei A. Gastrointestinal dopamine as an anti-incretin and its possible role in bypass surgery as therapy for type 2 diabetes with associated obesity. Minerva Endocrinol. 2016;41(1):43–56.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Tavares G, Martins FO, Melo BF et al. Peripheral dopamine directly acts on insulin-sensitive tissues to regulate insulin signaling and metabolic function. Front Pharmacol. 2021;12:713418. https://doi.org/10.3389/fphar.2021.713418.</mixed-citation><mixed-citation xml:lang="en">Tavares G, Martins FO, Melo BF et al. Peripheral dopamine directly acts on insulin-sensitive tissues to regulate insulin signaling and metabolic function. Front Pharmacol. 2021;12:713418. https://doi.org/10.3389/fphar.2021.713418.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Aslanoglou D, Bertera S, Sánchez-Soto M et al. Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors. Transl Psychiatry. 2021;11(1):59. https://doi.org/10.1038/s41398-020-01171-z.</mixed-citation><mixed-citation xml:lang="en">Aslanoglou D, Bertera S, Sánchez-Soto M et al. Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors. Transl Psychiatry. 2021;11(1):59. https://doi.org/10.1038/s41398-020-01171-z.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Wei H, Zapata RC, Lopez-Valencia M et al. Dopamine D2 receptor signaling modulates pancreatic beta cell circadian rhythms. Psychoneuroendocrinology. 2020;113:104551. https://doi.org/10.1016/j.psyneuen.2019.104551.</mixed-citation><mixed-citation xml:lang="en">Wei H, Zapata RC, Lopez-Valencia M et al. Dopamine D2 receptor signaling modulates pancreatic beta cell circadian rhythms. Psychoneuroendocrinology. 2020;113:104551. https://doi.org/10.1016/j.psyneuen.2019.104551.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Freyberg Z, McCarthy MJ. Dopamine D2 Receptors and the circadian clock reciprocally mediate antipsychotic druginduced metabolic disturbances. Schizophr. 2017;3(1). https://doi.org/10.1038/s41537-017-0018-4.</mixed-citation><mixed-citation xml:lang="en">Freyberg Z, McCarthy MJ. Dopamine D2 Receptors and the circadian clock reciprocally mediate antipsychotic druginduced metabolic disturbances. Schizophr. 2017;3(1). https://doi.org/10.1038/s41537-017-0018-4.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Song J, Kim J. Degeneration of dopaminergic neurons due to metabolic alterations and Parkinson’s disease. Front Aging Neurosci. 2016;8:65. https://doi.org/10.3389/fnagi.2016.00065.</mixed-citation><mixed-citation xml:lang="en">Song J, Kim J. Degeneration of dopaminergic neurons due to metabolic alterations and Parkinson’s disease. Front Aging Neurosci. 2016;8:65. https://doi.org/10.3389/fnagi.2016.00065.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Haas J, Berg D, Bosy-Westphal A, Schaeffer E. Parkinson’s disease and sugar intake-reasons for and consequences of a still unclear craving. Nutrients 2022;14(15):3240. https://doi.org/10.3390/nu14153240.</mixed-citation><mixed-citation xml:lang="en">Haas J, Berg D, Bosy-Westphal A, Schaeffer E. Parkinson’s disease and sugar intake-reasons for and consequences of a still unclear craving. Nutrients 2022;14(15):3240. https://doi.org/10.3390/nu14153240.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Liu S, Borgland SL. Insulin actions in the mesolimbic dopamine system. Exp Neurol. 2019;320:113006. https://doi.org/10.1016/j.expneurol.2019.113006.</mixed-citation><mixed-citation xml:lang="en">Liu S, Borgland SL. Insulin actions in the mesolimbic dopamine system. Exp Neurol. 2019;320:113006. https://doi.org/10.1016/j.expneurol.2019.113006.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Li H. Wu R, Xi Y et al. Dopamine 1 receptors inhibit apoptosis via activating CSE/H2 S pathway in high glucose-induced vascular endothelial cells. Cell Biol Int. 2022;46(7):1098−1108. https://doi.org/10.1002/cbin.11794.</mixed-citation><mixed-citation xml:lang="en">Li H. Wu R, Xi Y et al. Dopamine 1 receptors inhibit apoptosis via activating CSE/H2 S pathway in high glucose-induced vascular endothelial cells. Cell Biol Int. 2022;46(7):1098−1108. https://doi.org/10.1002/cbin.11794.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Nguanmoo PS, Tanajak P, Kerdphoo S et al. GLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. Toxicol Appl Pharmacol. 2017;333:43−50. https://doi.org/10.1016/j.taap.2017.08.005.</mixed-citation><mixed-citation xml:lang="en">Nguanmoo PS, Tanajak P, Kerdphoo S et al. GLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. Toxicol Appl Pharmacol. 2017;333:43−50. https://doi.org/10.1016/j.taap.2017.08.005.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Ter Horst KW, Lammers NM, Trinko R et al. Striatal dopamine regulates systemic glucose metabolism in humans and mice. Sci Transl Med. 2018;10:3752. https://doi.org/10.1126/scitranslmed.aar3752.</mixed-citation><mixed-citation xml:lang="en">Ter Horst KW, Lammers NM, Trinko R et al. Striatal dopamine regulates systemic glucose metabolism in humans and mice. Sci Transl Med. 2018;10:3752. https://doi.org/10.1126/scitranslmed.aar3752.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Pang Y, Lin S, Wright C et al. Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats. Neuroscience. 2016;318:157–165. https://doi.org/10.1016/j.neuroscience.2016.01.020.</mixed-citation><mixed-citation xml:lang="en">Pang Y, Lin S, Wright C et al. Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats. Neuroscience. 2016;318:157–165. https://doi.org/10.1016/j.neuroscience.2016.01.020.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Быков Ю.В., Батурин В.А. Определение уровней аутоантител к нейрорецепторам у детей больных сахарным диабетом 1-го типа. Патологическая физиология и экспериментальная терапия. 2022;66(4):61−66. https://doi.org/10.25557/0031-2991.2022.04.61-66</mixed-citation><mixed-citation xml:lang="en">Bykov YuV, Baturin VA. Determination of levels of autoantibodies to neuroreceptors in children with type 1 diabetes mellitus. Patologicheskaya fiziologiya i ehksperimental’naya terapiya = Pathological physiology and experimental therapy. 2022;66(4):61−66. https://doi.org/10.25557/0031-2991.2022.04.61-66.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
